Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

New Science Ventures

Investor type Micro VC
Founders Somu Subramaniam

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 75
Average round size
info
The average size of a deal this fund participated in
$24M
Portfolio companies 47
Rounds per year 4.17
Lead investments 18
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.37
Exits 16
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Manufacturing
Summary

In 2004 was created New Science Ventures, which is appeared as VC. The main office of represented VC is situated in the New York. The company was established in North America in United States.

The fund was created by Somu Subramaniam. We also calculated 8 valuable employees in our database.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Light Sciences Oncology, BioVex, Juventas Therapeutics We can highlight the next thriving fund investment areas, such as Medical Device, Pharmaceutical. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this New Science Ventures performs on 10 percentage points less the average number of lead investments. The top amount of exits for fund were in 2015. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the New Science Ventures, startups are often financed by Oxford Bioscience Partners, Easton Capital, Triathlon Medical Venture Partners. The meaningful sponsors for the fund in investment in the same round are Forbion Capital Partners, Easton Capital, Triathlon Medical Venture Partners. In the next rounds fund is usually obtained by Easton Capital, Oxford Bioscience Partners, OrbiMed.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of New Science Ventures:
Typical Co-investors
New Science Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after New Science Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Actium Funds Salt Lake City, United States, Utah
Asia Capital Colombo, Sri Lanka, Western Province
Baichuan Huida Touzi China, Guangdong, Tianjin
Capital Medica Ventures Chiyoda, Japan
Co-Share capital China, Guangdong, Guangzhou
Cognosante Mclean, United States, Virginia
Coral Reef IO England, London, United Kingdom
Falcon Capital England, London, United Kingdom
Koudai Jianzhi China, Guangdong, Guangzhou
Lotus -
Money Forward Chiyoda, Japan
Promus Capital Chicago, Illinois, United States
Q Investments Fort Worth, Texas, United States
River SaaS Capital Ohio, United States, Westlake
RRC Group Moscow, Moscow, Russia
Varsity Ventures California, Stanford, United States
Vertex Asia Fund Central, Central Region, Singapore
Xuebao No.1 Beijing, China, Haidian
Xuwei Investment China, Shanghai
Zhongyi Venture Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Novadip Biosciences

Biotechnology
Health Care
Medical
Therapeutics
$28M03 Nov 2022 Belgium, Walloon Brabant, Belgium

Paragraf

Advanced Materials
Electronics
Industrial Engineering
Manufacturing
Semiconductor
$60M01 Mar 2022 Huntingdonshire, England, United Kingdom

NorthSea Therapeutics

Biotechnology
Health Care
Therapeutics
$80M17 Dec 2021 The Netherlands, North Holland, Netherlands

Cambridge Epigenetix

Biotechnology
Health Care
Health Diagnostics
Medical
$88M02 Nov 2021 Cambridge, England, United Kingdom

Novadip Biosciences

Biotechnology
Health Care
Medical
Therapeutics
$22M28 Oct 2021 Belgium, Walloon Brabant, Belgium

BrightVolt

Battery
Electronics
Manufacturing
$16M06 Oct 2021 Washington, United States

Phase Four

Aerospace
Innovation Management
Space Travel
$26M11 Jun 2021 California, United States

Ventyx Biosciences

Biopharma
Biotechnology
$114M09 Mar 2021 Encinitas, California, United States

Zeotap

Digital Marketing
Marketing
SaaS
$42M15 Jul 2020 Berlin, Berlin, Germany
News
Isorg Raises €16M in Series C Financing

– Isorg from Limoges, France develops Organic Photodetectors (OPDs) and large-area image sensors.
– The company raised €16M in series C financing.
– Two major industrial investors – Sumitomo Chemical Co. Ltd and Mitsubishi Corporation participated in the round.
– Greece-based Integrated Systems Development SA and five new French investors represented by fund manager Financière Fonds Privés also joined the round.
– Legacy shareholders Bpifrance, through its large venture funds, New Science Venture, CEA Investment and Sofimac Group (Limousin Participations) also contributed.

Phase Four Raises $26m Series B led by New Science Ventures

– Phase Four announced a $26m Series B investment round.
– The round was led by New Science Ventures LLC.
– The new capital follows a year of significant growth for Phase Four.
– NSV is a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent New Science Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: